“Onychomycosis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Onychomycosis Market.
The Onychomycosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Onychomycosis Pipeline Report:
Companies across the globe are diligently working toward developing novel Onychomycosis treatment therapies with a considerable amount of success over the years.
Onychomycosis companies working in the treatment market are Moberg Pharma, Blueberry Therapeutics, Hallux, Pfizer, MediQuest Therapeutics, Polichem S.A, Repolar Ltd., Celtic Pharma, GlaxoSmithKline, Hisamitsu Pharma, Polichem S.A., Pfizer, Bausch Health, Halcygen Pharma, Meiji Seika Pharma, photonamic GmbH, Viamet, Novartis, Topica Pharma, Taro Pharma, NanoBio Crp, Hallux, Inc., Merck Sharp & Dohme, Bayer, Abeona Therapeutics, Dow Pharma, Taro Pharma, and others, are developing therapies for the Onychomycosis treatment
Emerging Onychomycosis therapies in the different phases of clinical trials are- MOB-015, BB2603, HSG, Tavaborole, MOB015B, P-3058, Organogel of naftifine, Amorolfine, TDT067 and Lamisil, Albaconazole, HTU-520, P-3058, AN2690, Efinaconazole, SUBA-itraconazole, ME1111, PD P 506 A, VT-1161, terbinafine, Luliconazole, NVXT topical, NB-002, HTS-519, SCH 56592, Bifonazole cream 1%, EcoNail™, IDP-108, Itraconazole, and others are expected to have a significant impact on the Onychomycosis market in the coming years.
Acquired by Pfizer, Anacor Pharmaceuticals Inc. has made notable advancements in the treatment of dermatophytic onychomycosis. Their topical antifungal product, Kerydin (tavaborole), is well-regarded for its effectiveness in treating onychomycosis.
Johnson & Johnson, via its subsidiary Janssen Pharmaceuticals, plays a significant role in the dermatophytic onychomycosis treatment market. The company’s focus on research and development has resulted in the development of effective antifungal treatments. Johnson & Johnson’s extensive distribution network and strong brand reputation ensure their treatments are widely accessible.
Onychomycosis Overview
Onychomycosis is a fungal infection that affects the nails, typically the toenails but sometimes the fingernails as well. This condition, also known as tinea unguium, is caused by various types of fungi, including dermatophytes, yeasts, and non-dermatophyte molds.
Get a Free Sample PDF Report to know more about Onychomycosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/onychomycosis-pipeline-insight
Emerging Onychomycosis Drugs Under Different Phases of Clinical Development Include:
MOB-015: Moberg Pharma
BB2603: Blueberry Therapeutics
HSG: Hallux
Tavaborole: Pfizer
MOB015B: Moberg Pharma AB
P-3058: Polichem S.A.
Organogel of naftifine: MediQuest Therapeutics
Amorolfine: Repolar Ltd.
TDT067 and Lamisil: Celtic Pharma
Albaconazole: GlaxoSmithKline
HTU-520: Hisamitsu Pharma
P-3058: Polichem S.A.
AN2690: Pfizer
Efinaconazole: Bausch Health
SUBA-itraconazole: Halcygen Pharma
ME1111: Meiji Seika Pharma
PD P 506 A: photonamic GmbH
VT-1161: Viamet
terbinafine: Novartis
Luliconazole: Topica Pharma
NVXT topical: Taro Pharma
NB-002: NanoBio Crp
HTS-519: Hallux, Inc.
SCH 56592: Merck Sharp & Dohme
Bifonazole cream 1%: Bayer
EcoNail™: Abeona Therapeutics
IDP-108: Dow Pharma
Itraconazole: Taro Pharma
Onychomycosis Route of Administration
Onychomycosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Onychomycosis Molecule Type
Onychomycosis Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Onychomycosis Pipeline Therapeutics Assessment
Onychomycosis Assessment by Product Type
Onychomycosis By Stage and Product Type
Onychomycosis Assessment by Route of Administration
Onychomycosis By Stage and Route of Administration
Onychomycosis Assessment by Molecule Type
Onychomycosis by Stage and Molecule Type
DelveInsight’s Onychomycosis Report covers around 11+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Onychomycosis product details are provided in the report. Download the Onychomycosis pipeline report to learn more about the emerging Onychomycosis therapies
Some of the key companies in the Onychomycosis Therapeutics Market include:
Key companies developing therapies for Onychomycosis are – Bausch Health Companies, Celtic Pharma, Galderma S.A., Johnson & Johnson, Anacor Pharmaceuticals Inc., Pfizer Inc., GlaxoSmithKline Plc, Novartis AG, Topica Pharmaceuticals Inc., Bayer AG, Moberg Pharma AB, Allergen Inc., Cipla Ltd, Reddy’s Laboratories Ltd, Sanofi S.A., Merz Pharma, Medimetriks Pharmaceuticals Inc., NovaBiotics Inc., ZimVie Inc., Wieland Dental, Teva Pharmaceutical Industries Ltd., Cardinal Health Inc., Zimmer Biomet, ZimVie Inc., Lumenis Ltd, Blueberry Therapeutics, Viatris Inc., Cardinal Health Inc., Valeant Pharmaceuticals International Inc., IMARC Group, Almirall S.A., and others.
Onychomycosis Pipeline Analysis:
The Onychomycosis pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Onychomycosis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Onychomycosis Treatment.
Onychomycosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Onychomycosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Onychomycosis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Onychomycosis drugs and therapies
Onychomycosis Pipeline Strengths
The introduction of novel, inexpensive, and non-invasive diagnostic technologies have led to rapid and accurate diagnosis of onychomycosis, hence increasing the rate of diagnosis.
Onychomycosis Pipeline Market Opportunities
Current treatments have poor adherence and tolerability creating an opportunity for the key players to work on these areas
Scope of Onychomycosis Pipeline Drug Insight
Coverage: Global
Key Onychomycosis Companies: Moberg Pharma, Blueberry Therapeutics, Hallux, Pfizer, MediQuest Therapeutics, Polichem S.A, Repolar Ltd., Celtic Pharma, GlaxoSmithKline, Hisamitsu Pharma, Polichem S.A., Pfizer, Bausch Health, Halcygen Pharma, Meiji Seika Pharma, photonamic GmbH, Viamet, Novartis, Topica Pharma, Taro Pharma, NanoBio Crp, Hallux, Inc., Merck Sharp & Dohme, Bayer, Abeona Therapeutics, Dow Pharma, Taro Pharma, and others
Key Onychomycosis Therapies: MOB-015, BB2603, HSG, Tavaborole, MOB015B, P-3058, Organogel of naftifine, Amorolfine, TDT067 and Lamisil, Albaconazole, HTU-520, P-3058, AN2690, Efinaconazole, SUBA-itraconazole, ME1111, PD P 506 A, VT-1161, terbinafine, Luliconazole, NVXT topical, NB-002, HTS-519, SCH 56592, Bifonazole cream 1%, EcoNail™, IDP-108, Itraconazole, and others
Onychomycosis Therapeutic Assessment: Onychomycosis current marketed and Onychomycosis emerging therapies
Onychomycosis Market Dynamics: Onychomycosis market drivers and Onychomycosis market barriers
Request for Sample PDF Report for Onychomycosis Pipeline Assessment and clinical trials
Table of Contents
1. Onychomycosis Report Introduction
2. Onychomycosis Executive Summary
3. Onychomycosis Overview
4. Onychomycosis- Analytical Perspective In-depth Commercial Assessment
5. Onychomycosis Pipeline Therapeutics
6. Onychomycosis Late Stage Products (Phase II/III)
7. Onychomycosis Mid Stage Products (Phase II)
8. Onychomycosis Early Stage Products (Phase I)
9. Onychomycosis Preclinical Stage Products
10. Onychomycosis Therapeutics Assessment
11. Onychomycosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Onychomycosis Key Companies
14. Onychomycosis Key Products
15. Onychomycosis Unmet Needs
16 . Onychomycosis Market Drivers and Barriers
17. Onychomycosis Future Perspectives and Conclusion
18. Onychomycosis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
